Important Innovations

  COVID Kids' Vaccine Moves Forward                            Source:  Pfizer-BioNTech COVID Vaccine 100% Effective in Initial Data From Trials Germany based BioNTech and Pfizer announced today that their COVID-19 vaccine is 100% effective in teens, according to their initial data from ongoing trials in children from 12 to 15 years old.  The companies added kids tolerate the vaccine very well.  Their vaccine has already been approved for emergency use in young people 16 year old plus and adults.  The companies, based on their new data, say that they believe it is safe and effective for kids 12 to 15 years old to receive the two shot vaccine.  Their data is being forwarded to the FDA for its review and possible approval for use in young teens to protect them from COVID.  The companies hope to start vaccinating kids before the start of the new school year in fall of 2021. Testing Ongoing For Kids of All Ages The Pfizer-BioNTech vaccine has been shot into the arms of hundreds of mill

Germany's BioNTech & Pfizer Test COVID Vaccine for Kids                                                             Source:  Stock Image of Child & Vaccine                                                            Source:  BioNTech & Pfizer Breakthrough Medical Innovation Pfizer and its German partner BioNTech hope to be able to vaccinate children under 12 years old against COVID-19 by early 2022.  Early stage trials started in late March 2021.  The volunteers (via their parents) are as young as 6 months old.  The Pfizer BioNTech COVID vaccine for adults was the first authorized for use in the US in mid December 2020 and among the first to hit global markets in late fall 2020. In the US alone, 66 million people have received it. Shot In The Arm Only the Pfizer BioNTech vaccine is being used on 16 and 17 year old teens in the US.  Moderna's vaccine has been cleared for those 18 years and older.  No vaccine has been authorized for use on children under 16 year old in

  COVID Vaccines Very Close to Market                                             Source:  Moderna Hope For a COVID Weary World Moderna, headquartered in Cambridge, MA, is seeking US, EU and UK emergency authorization for their COVID vaccine.  The vaccine has proved to be 94% effective.  The company adds it has no serious side effects. Highly Effective More than 1.5 million people have died from COVID.  Moderna says the vaccine is 100% effective in preventing severe cases of COVID.  It also works across demographic groups, including age, gender, ethnicity and race. Second COVID Vaccine Close to Market This is the second vaccine that is now under review for emergency authorization.  The other vaccine was developed by Pfizer and its German biotech partner BioNTech.  That vaccine is 95%.  Both the Pfizer and the Moderna vaccines could be on the market within two weeks.  Both vaccines were developed with a new technology called messenger RNA (mRNA).  Moderna says it will have 20 million do

  Pfizer To Request Quick Emergency FDA Approval Source:  Pfizer COVID Vaccine Suddenly There Is Hope    Pfizer has completed its late stage trial of its COVID-19 vaccine, saying it is 95% effective.  The company adds that it is effective on older adults, who are more vulnerable, and works against both mild and severe cases of COVID.  The company has the required 2 months of safety data for regulators.  Within days, Pfizer says it will apply for emergency FDA approval to start making it available for public use.  The vaccine's efficacy rate is the highest among all current vaccine candidate now in trials.  As the Economist magazine put it "Suddenly There is Hope". "The Speed of Science" Pfizer expects that the FDA will hold a public hearing on their vaccine in December.  Pfizer CEO Albert Bourla says knowing that every day matters in the fight against COVID, the company is moving at what he calls "the speed of science".  The vaccine was developed joint

  1st Pfizer/BioNTech COVID Vaccine,  Now Moderna Vaccine                                    Source: Moderna COVID Vaccine Moderna Vaccine is 94.5% Effective, Pfizer More than 90% More hope in the fight against the COVID-19 global pandemic.  Cambridge, MA based biotech Moderna reports that it has a COVID vaccine candidate that is 94.5% effective against the deadly virus .  COVID-19 has infected more than 55 million people and taken more than 1.3 million lives globally as of today.  Pfizer/Germany's BioNTech Vaccine Moderna has the second highly acclaimed vaccine candidate since Pfizer/BioNTech announced theirs a few days ago.  Pfizer claims their vaccine has a more than 90% effective rate. These vaccines have to be approved by regulatory authorities, but their results look very promising and are giving global medical experts hope of quick turnaround deployments. Dr. Anthony Fauci's Take The US's top infectious disease expert Dr. Anthony Fauci says that he is optimistic abou

  German Biotech BioNTech's & Pfizer's New COVID Vaccine                                                  Source:  BioNTech 1st Vaccine Against COVID that Appears Effective COVID-19 has caused more than 1 million deaths and infected 52 million people worldwide.  Finding a vaccine to protect the world against this unrelenting disease is the Holy Grail of medical research. Frankfurt, Germany based BioNTech appears to be the first to have produced a vaccine that is effective against COVID.  The company is co-developing the vaccine with Pfizer. Below Market Rate Vaccine Pricing BioNTech plans to price the vaccine, which requires two shots, at below "typical market rates".  It will also differentiate the price among countries and regions.  The company is doing so to ensure broad-based access around the world.  It is important to note that the vaccine has not yet won regulatory approvals. Efficacy Rates Based on preliminary trial data, the vaccine is 90% effective.  Wit